Efinopegdutide
Also known as: GLP-1/glucagon dual agonist, MK-6024, HM12525A, efino
Dual GLP-1 and glucagon receptor agonist studied for fatty liver disease and metabolic syndrome.
Quick Reference
Efinopegdutide - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Pharmaceutical compound
Efinopegdutide (MK-6024) is a dual agonist of the glucagon and GLP-1 receptors. It is being developed by Merck for non-alcoholic fatty liver disease. It was also developed for type 2 diabetes and obesity but these indications were discontinued.
Mechanism of Action
Efinopegdutide (MK-6024) is a dual agonist of the glucagon and GLP-1 receptors. It is being developed by Merck for non-alcoholic fatty liver disease. It was also developed for type 2 diabetes and obesity but these indications were discontinued.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
Efinopegdutide (also known as GLP-1/glucagon dual agonist, MK-6024) is studied within the metabolic health research community. Dual GLP-1 and glucagon receptor agonist studied for fatty liver disease and metabolic syndrome.
Last updated October 28, 2026
Research status: emerging. Efinopegdutide appears across metabolic health research forums and academic literature. Researchers note this compound falls in the metabolic category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with Efinopegdutide. Comments are reviewed before appearing.